Literature DB >> 19101837

In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.

Gloria M González1.   

Abstract

The in vitro activity of isavuconazole was compared to those of amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, and ravuconazole against 300 clinical isolates of Pseudallescheria boydii, Paecilomyces lilacinus, Fusarium spp., Bipolaris spicifera, Curvularia lunata, Alternaria alternata, Exophiala spp., Rhizopus arrhizus, Mucor circillenoides, Absidia corymbifera, Blastomyces dermatitidis, Histoplasma capsulatum and Coccidioides posadasii. MICs were determined by a broth macrodilution method based on the CLSI M38-A procedure. The triazoles were relatively uniform in that they showed strong in vitro inhibitory activity against most of the tested fungi. In vitro activity was variable with strains of P. lilacinus while with Fusarium spp., the triazoles were found to have limited in vitro activity and amphotericin B was moderately active. The results suggest that isavuconazole is a broad-spectrum antifungal agent, effective against a wide range of moulds in vitro.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101837     DOI: 10.1080/13693780802562969

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  24 in total

Review 1.  Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

Authors:  George R Thompson; Nathan P Wiederhold
Journal:  Mycopathologia       Date:  2010-06-05       Impact factor: 2.574

2.  In Vitro Susceptibility of Fusarium to Isavuconazole.

Authors:  A Broutin; J Bigot; Y Senghor; A Moreno-Sabater; J Guitard; C Hennequin
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

3.  In vitro antifungal susceptibility profile and correlation of mycelial and yeast forms of molecularly characterized Histoplasma capsulatum strains from India.

Authors:  Shallu Kathuria; Pradeep K Singh; Jacques F Meis; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

4.  Use of Antifungal Combination Therapy: Agents, Order, and Timing.

Authors:  Melissa D Johnson; John R Perfect
Journal:  Curr Fungal Infect Rep       Date:  2010-05-01

5.  Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.

Authors:  Mahdi Abastabar; Abdullah M S Al-Hatmi; Mohammad Vafaei Moghaddam; G Sybren de Hoog; Iman Haghani; Seyed Reza Aghili; Tahereh Shokohi; Mohammad Taghi Hedayati; Roshanak Daie Ghazvini; Reza Kachuei; Ali Rezaei-Matehkolaei; Koichi Makimura; Jacques F Meis; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Use of amplified fragment length polymorphism to identify 42 Cladophialophora strains related to cerebral phaeohyphomycosis with in vitro antifungal susceptibility.

Authors:  Hamid Badali; G Sybren de Hoog; Ilse Curfs-Breuker; Corné H W Klaassen; Jacques F Meis
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

7.  In Vitro Activities of Ravuconazole and Isavuconazole against Dematiaceous Fungi.

Authors:  Hailin Zheng; Nana Song; Huan Mei; Jiacheng Dong; Dongmei Li; Xiaofang Li; Weida Liu
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 8.  Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.

Authors:  Matthew W McCarthy; Brad Moriyama; Ruta Petraitiene; Thomas J Walsh; Vidmantas Petraitis
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

9.  Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.

Authors:  Shawn R Lockhart; Elizabeth L Berkow
Journal:  Clin Microbiol Newsl       Date:  2016-07

10.  In vitro antifungal activity of isavuconazole against Madurella mycetomatis.

Authors:  Wendy Kloezen; Jacques F Meis; Ilse Curfs-Breuker; Ahmed H Fahal; Wendy W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.